When To Choose VABB And When To Choose CNB

Jun 12, 2026

https://pmc.ncbi.nlm.nih.gov/articles/PMC4115763/

Breast biopsy is not a universal one-size-fits-all solution; distinct clinical scenarios impose vastly different requirements on biopsy techniques. This article explores the optimal application windows for Vacuum-Assisted Breast Biopsy (VABB) and conventional Core Needle Biopsy (CNB) from three perspectives: lesion imaging features, patient physical conditions, and subsequent therapeutic plans.

1. Selection Based on Imaging Manifestations of Lesions

Ultrasound-visible solid masses (≥1 cm): CNB suffices for definitive diagnosis. The standard protocol involves 2–4 punctures with 14G or 16G needles under local anesthesia to harvest adequate tissue for pathological grading. The spring-driven force of CNB easily penetrates firm lesions such as invasive ductal carcinoma.
Clustered microcalcifications (BI-RADS 4C/5): VABB is strongly recommended. Calcified lesions are often small and scattered, making random CNB sampling prone to missed targets. Under stereotactic guidance, VABB achieves en bloc resection of the entire calcified region for pathological testing, delivering a diagnostic accuracy exceeding 98%.
Non-mass enhancement lesions detected by MRI: Real-time needle visualization is unavailable during MRI-guided procedures, raising blind puncture risks for CNB. Vacuum suction stabilizes tissue for VABB, and laser-etched markers on the cannula remain clearly visible under MRI-compatible coils. VABB is currently the only officially approved biopsy modality for MRI guidance.

2. Adjustment According to Special Patient Conditions

Small breast volume or lesions adjacent to the chest wall/skin: The long spring stroke of CNB may overpenetrate targets, triggering pneumothorax or cutaneous indentation. VABB features a shorter cutting cannula, and negative vacuum tension draws tissue inward to reduce perforation hazards. VABB needles produced by Manners are fabricated from 316L stainless steel with HRC 30–40 hardness, balancing rigidity and ductility for delicate manipulations in these cases.
Coagulopathy or patients on anticoagulants: VABB's simultaneous suction-and-cut mechanism compresses microvessels instantly during sampling. Its postoperative hematoma rate (~1.5%) is markedly lower than CNB's (~4%). Multiple clinical guidelines prioritize VABB for patients with INR >1.5.
Multifocal or multicentric lesions: VABB enables multi-angle repeated sampling from a single skin entry point, whereas CNB demands full repositioning for every puncture. For bilateral lesions or multi-quadrant unilateral disease, VABB cuts total procedural time and radiation exposure.

3. Matching Based on Requirements for Subsequent Treatment Planning

Molecular subtyping prior to neoadjuvant chemotherapy: VABB yields abundant tissue to support IHC assays for ER, PR, Ki-67 and HER2, plus FISH testing. CNB specimens frequently suffer cellular distortion from compression, interfering with pathological interpretation.
Preoperative localization marking for planned breast-conserving surgery: VABB allows deployment of metallic marker clips concurrent with biopsy to guide subsequent surgical resection. Some VABB platforms integrate radiofrequency ablation, enabling one-stop diagnosis and residual lesion ablation.
Complete resection of benign lesions: VABB acts as a minimally invasive rotational resection tool for fibroadenomas or papillomas, removing lesions entirely to eliminate the need for open surgery. CNB only retrieves partial tissue samples and cannot achieve curative resection.

Conclusion

Clinical decision-making follows the principle: lesion characteristics as the primary determinant, patient status as adjustment factors, and therapeutic demands as the guiding objective. CNB covers most routine diagnostic cases, while VABB delivers irreplaceable advantages for complex, high-risk, and high-precision scenarios. Complementary deployment of the two techniques forms a comprehensive toolkit for modern breast interventional pathology.